Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported results from a Phase 1 study evaluating the safety and efficacy of antolimab for the treatment of patients with mast cell gastrointestinal disease.
REDWOOD CITY, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Allakos, Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported results from a Phase 1 study evaluating the safety and efficacy of antolimab for the treatment of patients with mast cell gastrointestinal disease.
Mast Cell Gastrointestinal Disease
During enrollment of the Company’s Phase 2 ENIGMA study in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), patients were identified with chronic moderate to severe gastrointestinal symptoms and elevated stomach and/or duodenal mast cell counts who did not have elevated eosinophils counts. These patients appeared to have a mast cell driven condition, currently referred to as mast cell gastrointestinal disease (MGID), and were offered the opportunity to participate in an open-label study of antolimab.
Phase 1 MGID Study Design
This open-label, multi-dose, 6-month, Phase 1 trial of antolimab consisted of seven patients with moderate to severe gastrointestinal symptoms and elevated mast cells (≥30 mast cells per hpf in at least 5hpfs in the stomach and/or ≥30 mast cells per hpf in at least 3hpfs in the duodenum) who did not have elevated eosinophils. Patients received 0.3 mg/kg of antolimab for the first dose, followed by 1.0 mg/kg the following month, then monthly doses of 3.0 mg/kg for four additional months. Disease symptoms were assessed using a daily patient reported questionnaire measuring eight symptoms (Total Symptom Score [TSS-8: abdominal pain, nausea, vomiting, early satiety, loss of appetite, abdominal cramping, bloating, and diarrhea]).
Study Results
Six-month treatment with antolimab resulted in a 64 percent mean reduction in TSS-8 compared to baseline. Five of seven (71 percent) patients had >50 percent reduction in TSS-8. The treatment effect of antolimab in this open label study was similar to that observed with antolimab in patients with EG and/or EoD in the Phase 2 ENIGMA Study.
| Tissue and Symptom Results | MGID (N=7) | ||
| Baseline | % Change | ||
| Change in median GI eosinophil counts | 17 eos/hpf | -100 | % |
| Change in median GI mast cell counts | 55 mc/hpf | -18 | % |
| Mean change in Total Symptom Score (TSS-8) | 27.1 | -64 | % |
Safety
Antolimab was generally well tolerated and no drug-related serious adverse events occurred during the study. The most common treatment emergent adverse event was infusion related reactions, all of which were mild.
Given the encouraging treatment response observed in this study, MGID may represent a novel market opportunity. Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.
Conference Call and Live Webcast
The Company will host a conference call and webcast with slides today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial 877-407-9039 (domestic) or 201-689-8470 (international). The conference ID number is 13700828. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at www.allakos.com. The archived audio webcast will remain available on the Company’s website for 30 days following the conference call.
About Allakos
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab has been tested in six clinical studies. In these studies, antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company’s website at www.allakos.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ early stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize antolimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals and appropriate labelling for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond antolimab (AK002); Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on February 25, 2020, and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release.
Source: Allakos Inc.
Investor Contact: Adam Tomasi, President and COO ir@allakos.com Media Contact: Denise Powell denise@redhousecomms.com
